Watch BCAB. Know when insiders buy.
One email the day a filing lands. Free.
BCAB
BioAtla, Inc.
1.26
−0.06 −4.55%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $40.7MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$31.5MNET CASH —52W 1.08 – 61.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | $227K | $452K | — | 0.27 | −$419K | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$9.3M | −$6.3M | — | -4.22 | −$5.3M | — | — | May 15 |
| Q4 2025 · Dec 31derived | — | — | — | −$9.3M | −$9.8M | — | -0.16 | −$7.9M | — | — | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$13.8M | −$15.8M | — | -0.27 | −$9.9M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$18.6M | −$18.7M | — | -15.99 | −$14.1M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$17.6M | −$15.3M | — | -13.16 | −$16.3M | — | — | May 15 |
| Q4 2024 · Dec 31derived | — | — | — | −$16.2M | −$14.9M | — | -0.30 | −$16.8M | — | — | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$11.3M | −$10.6M | — | -0.22 | −$5.1M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$22M | −$21.1M | — | -0.44 | −$19.2M | — | — | Aug 7 |
| Q1 2024 · Mar 31 | — | — | — | −$24.5M | −$23.2M | — | -0.48 | −$30.8M | — | — | May 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$28.5M | −$26.9M | — | -0.56 | −$29.9M | — | — | Mar 28 |
| Q3 2023 · Sep 30 | $0 | — | — | −$35M | −$33.3M | — | -0.70 | −$27.3M | — | — | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$59.3M | −$59.6M | — | -1.01 | −$48.2M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$73.9M | −$69.8M | — | -1.44 | −$71.9M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$129.7M | −$123.5M | — | -2.58 | −$104M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$108.1M | −$106.5M | — | -2.74 | −$90.4M | — | — | — | — |
| FY2021 · to Dec 31 | $300K | — | −$96.4M | −$95.4M | -31800.7% | -2.76 | −$62.2M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$30.1M | −$35.9M | — | -3.19 | −$36.3M | — | — | — | — |
Every number comes from BioAtla, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.